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Acute kidney injury (AKI) complicates about 3–50 % of
hospital admissions [1] depending on patient comorbidi-
ties and on medical procedures performed during the
stay. The greatest incidence of AKI is observed in the in-
tensive care unit (ICU): indeed, critically ill patients with
hospital‐acquired AKI have a greater in‐hospital mortal-
ity (30–70 %) and a more than double risk of severe
adverse outcomes even 5 years after discharge, including
an increased incidence of end‐stage chronic kidney
disease (CKD), than patients without AKI [2]. The most
common cause of in‐hospital AKI is sepsis, the systemic
inflammatory response to infection that is often compli-
cated by multiple organ failure and death [3]. In recent
years, experimental and clinical studies have provided
new insights into the pathogenic mechanisms of sepsis‐
associated AKI, also explaining how the loss of renal
function may impair the immune system and lead to the
subsequent development of sepsis. In this chapter, we* Correspondence: vincenzo.cantaluppi@med.uniupo.it
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© 2016 Dellepiane et al.review the recent findings on the detrimental cross‐talk
between sepsis and AKI and the identification of new,
early biomarkers and targeted therapies aimed at im-
proving the outcome of these critically ill patients.New pathogenic mechanisms of sepsis‐associated
aki: the ‘liaison dangereuse’ revisited
Major advances have been made in our understanding of
the detrimental connection between the systemic inflam-
matory response to infection and the acute loss of kid-
practice. In particular, recent findings have challenged
the dogma that in the course of severe sepsis and septic
shock, AKI is merely a consequence of ischemic damage
due to tissue hypoperfusion (Fig. 1).Renal overflow rather than hypoperfusion
According to old theories, tissue hypoperfusion associ-
ated with sepsis causes renal ischemia and consequently
acute tubular necrosis. By contrast, AKI is also found in
the early phases of severe sepsis even in absence of an
impaired cardiac output and in milder infectious dis-
eases without manifest systemic signs. In a large pro-
spective study including more than 1800 patients,
Murugan et al. reported that AKI was frequent in pa-
tients with non‐severe pneumonia, including those not
transferred to the ICU and without hemodynamic in-
stability [3]. In addition, the few studies reporting data
on biopsies or autopsies from patients who developed
sepsis‐associated AKI have demonstrated that tubular
necrosis is not common. Moreover, the number of apop-
totic cells is significantly lower than that observed in any
other types of AKI and not related to the severity of
renal dysfunction [4]. On this basis, it is now accepted
that septic AKI is only in part sustained by renal hypo-
































Fig. 1 Pathogenetic mechanisms of sepsis‐associated acute kidney injury (AKI). Systemic inflammation coupled with multi‐organ failure induces
renal injury through several mechanisms: renal hemodynamic changes, activation of immune cells, massive release of inflammatory molecules
and endocrine dysregulation. All contribute to glomerular and tubular cell injury. NO: nitric oxide; NE: norepinephrine; RAAS: renin‐angiotensin‐
aldosterone system; GFR: glomerular filtration rate; PAMP: pathogen‐associated molecular pattern; TEC: tubular epithelial cells; : decreased
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jected to invasive monitoring of renal blood flow (RBF)
[5]. Interestingly, these authors found that RBF was nor-
mal or even increased in sepsis and proposed the new
model of hyperdynamic septic AKI [5]. Furthermore, in-
creased RBF in septic AKI has also been observed in
humans using thermodilution and magnetic resonance
imaging (MRI) [6]. As a proof of concept, other studies
have confirmed in vitro that plasma obtained from pa-
tients with sepsis‐associated AKI induced tubular epithe-
lial cell dysfunction without the contribution of any
ischemia‐reperfusion injury [7].
Based on these data, septic AKI is currently considered
to be the consequence of several concomitant factors: a
dysfunction of the renal microvascular system; direct
interaction of pathogen fragments with renal residentcells; the cytotoxic effect of the sepsis‐induced cytokine
storm; and, finally, the deleterious cross‐talk between in-
jured organs. All these changes are sustained by fascinat-
ing intracellular mechanisms that may be targeted by
new therapeutic approaches.
Microvascular and glomerular changes in septic AKI
The parenchymal distribution of blood flow during sep-
sis is still far from being completely understood: the only
incontestable point is the concomitant reduction in the
glomerular filtration rate (GFR). For this reason, several
studies have focused on the mechanisms that decouple
RBF from GFR. It has been shown that sepsis triggers
a redistribution of RBF that leads to relative cortical
hypoperfusion and to medullary overflow: this effect
is enhanced by administration of norepinephrine [8].
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gish and congested, probably as the result of a high cap-
acity and low resistance circulation [9]. Other theories
about the GFR decline during sepsis have focused on the
reduction of filtration pressure not necessarily associated
with glomerular hypoperfusion; renal and central (CVP)
venous pressures are frequently increased in sepsis as a
possible consequence of the so‐called fluid challenge of
septic patients in the first hours after ICU admission. This
relative venous hypertension may induce microvascular
congestion and tissue edema, thus affecting GFR. In
support of this hypothesis, a retrospective analysis of
105 ICU patients found a linear correlation between
the CVP and AKI incidence or duration [10]. More-
over, it has been shown that fluid overload in septic
patients is independently associated with death and
worse renal outcomes [11]. Another theory is based
on the presence of efferent arteriole over‐dilation as a
consequence of altered angiotensin signaling or re-
gional differences in nitric oxide (NO) and norepin-
ephrine production and/or sensitivity [8]. The role of
norepinephrine seems particularly relevant within the
renal parenchyma: preliminary clinical and experimen-
tal studies have reported that the use of sympatholytic
agents, such as clonidine or the $\upalpha$‐2 receptor
antagonist, dexmedetomidine, improves outcomes in sep-
tic AKI [12]. It has also been proposed that inflammation‐
activated shunt systems may directly connect afferent and
efferent arterioles, thus decreasing GFR. However, al-
though this effect is present in experimental studies in
large animals subjected to sepsis, it has not been yet rec-
ognized in humans [8]. Finally, tubular cell dysfunction
(see next paragraph) may induce the back‐leakage of fil-
tered substances and a resultant GFR decrease completely
independent from glomerular physiology.
Systemic inflammation directly affects tubular cell
function
Sepsis comprises the concomitant presence of an
invasive infection and a host systemic inflammatory re-
sponse syndrome (SIRS). SIRS is characterized by an
over‐inflammatory state due to a massive and deregu-
lated activation of innate andadaptive immunity usually
followed by an equally massive and deleterious counter‐
regulatory response leading to the so‐called ‘immune
paralysis’. Accordingly, a bi‐modal trend in patient mor-
tality has been described with a first early phase due to
SIRS and a second late phase caused by immunosup-
pression and lymphocyte exhaustion [13].
As stated above, renal inflammatory injury may be
consequent to the direct interaction of resident cells
with pathogens as well as with molecules released fol-
lowing the deregulated host immune response. Different
pathogen‐associated molecular patterns (PAMPs), suchas lipopolysaccharide (LPS), lipoteichoic acid and porins,
may directly interact with resident kidney cells. In par-
ticular, tubular epithelial cells express Toll‐like receptor
4 (TLR4), the molecule with the highest affinity for LPS.
It has been shown that LPS reduces the expression of
the endocytic receptors megalin and cubilin in the apical
compartment of proximal tubular epithelial cells, leading
to an interference with the normal processes of protein
re‐absorption, thus contributing to the typical low mo-
lecular weight proteinuria of septic patients [7].
Renal resident endothelial and tubular cells directly
communicate with the immune system: indeed, these
cells not only express cytokine receptors, but they are
also able to release several inflammatory proteins and to
increase the expression of specific adhesion molecules
able to recruit circulating cells that perpetuate tissue
damage. It has also been demonstrated that tubular epi-
thelial cells can recruit T cells by expressing vascular cell
adhesion molecules (VCAMs) and intercellular cell
adhesion molecules (ICAMs) and that they are conse-
quently able to activate lymphocytes via the co‐stimulatory
molecule CD40 [14].
Circulating inflammatory cytokines directly affect the
renal parenchyma and are associated with an increased
risk of mortality in AKI patients [15]. The prominent
role of cytokines in septic patients was further
highlighted by a recent randomized controlled trial
based on the administration of afelimomab (an anti‐
tumor necrosis factor [TNF]‐α monoclonal antibody).
Patients with higher basal levels of interleukin (IL)‐6 had
a small but significant mortality reduction when treated
with this monoclonal antibody and, although the authors
did not focus on AKI incidence, a significant improve-
ment in the overall sequential organ failure assessment
(SOFA) score was observed 48 h after the infusion [16].
Of interest, some of these inflammatory mediators, such
as TNF‐α, IL‐6, CD40‐ligand and Fas‐ligand, can directly
interact with specific counter‐receptors located on tubu-
lar epithelial cells causing loss of function and apoptotic
cell death.
A further mechanism of renal injury in the course of
sepsis is probably linked to detrimental organ crosstalk.
Apart from the validated models of hepatorenal and car-
diorenal syndromes, recent studies have highlighted the
effect of lung, brain and bone marrow as sources of po-
tential nephrotoxic molecules. Indeed, studies performed
in vivo and in vitro using plasma derived from patients
treated with mechanical invasive ventilation showed that
pneumocytes produce IL‐1β, IL‐6, IL‐8 and TNF‐α after
ventilator‐induced biotrauma and that the release of
these cytokines promoted tubular cell apoptosis and
consequently AKI. Moreover, the massive cytokine re-
lease observed after traumatic brain injury is a putative
further cause of tubular cell dysfunction and has been
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graft function after donation for kidney transplantation
[14]. The mechanisms of interaction between systemic
inflammation and tubular epithelial cells and the poten-
tial clinical consequences of sepsis‐associated AKI are
shown in detail in Fig. 2.
Mechanisms of cellular dysfunction
All the hemodynamic and cytotoxic alterations described
in the previous paragraphs directly affect kidney cell
survival and function. Several types of cellular injury
occur in the course of AKI, including necrosis, apop-
tosis or their combined form, necroptosis. This latter
type of cellular injury is a highly immunogenic form
of programmed cell death that normally represents a
defense against viruses expressing caspase‐8 inhibitors,




















Fig. 2 Interplay between tubular epithelial cells and systemic inflammation
specific membrane receptors able to modulate cytokines, activated immun
tubular cells dedifferentiate and release a plethora of paracrine factors as a
tubular cells directly contribute to systemic inflammation by carrying out im
and activationThe role of this pathway in AKI has not been com-
pletely investigated.
As noted earlier, at biopsy or autopsy, septic patients
have a significantly lower rate of tubular apoptosis than
other ICU patients with AKI. Furthermore, the amount
of necrosis also seems to be marginal. In addition, both
apoptosis and necrosis are found in a few limited paren-
chymal areas and do not correlate with renal dysfunction
and AKI duration. The direct consequence of these ob-
servations is that septic AKI is probably associated with
a series of cell dysfunctions rather than cell death. Avail-
able histological data have demonstrated mostly tubular
cell vacuolization and mitochondrial rarefaction, possible
consequences of autophagy and mitophagy, respectively.
Based on these findings, it has been proposed that tubu-
lar epithelial cells react to injury by regressing to a dedif-






















. Tubular epithelial cells are directly targeted by inflammation through
e cells and bacterial products. In response to these deleterious stimuli,
n ultimate effort to induce tissue regeneration. On the other hand,
mune functions, such as cytokine release and leukocyte recruitment
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tion is significantly reduced [17]. The auto‐digestion of
energy‐consuming organelles (autophagy), including the
mitochondria (mitophagy), is one of the key passages of
this biological phenomenon. Moreover, it has been
shown that tubular cells exposed to septic plasma lose
cell polarity and the expression of the endocytic recep-
tor, megalin [7]. These alterations confirmed the transi-
tion of tubular cells toward a dedifferentiated state with
the consequent loss of preservation of two distinct fluid‐
filled compartments characterized by precise electrolyte
concentrations. As a consequence of tubular dysfunction,
both electrolyte reabsorption and protein trafficking are
almost completely abolished during septic AKI [7].
Another energy‐sparing strategy is the arrest of the
cell cycle. This phenomenon has been demonstrated
in tubular cells subjected to a septic microenvironment.
Accordingly, two of the most promising urine early bio-
markers of AKI (tissue inhibitor of metalloproteinases
[TIMP]‐2 and insulin‐like growth factor‐binding protein
[IGFBP]‐7) are proteins involved in the G1‐S phase transi-
tion arrest [18]. A further mechanism of tubular dysfunc-
tion may depend on the horizontal cross signaling
between proximal and distal segments. Kalakeche et al. re-
ported that cellular uptake of LPS in the S1 segment
caused oxidative stress at both S2 and S3 levels [19].
Finally, recent data suggest that AKI may contribute to
the development and aggravation of a systemic inflam-
matory state. Indeed, tubular cells are immunologically
active, because they are able to act as antigen‐presenting
cells and are devoted to the clearance of various soluble
mediators involved in inflammation. These findings may
at least in part explain the pathogenic mechanisms
underlying the accelerating development of sepsis and
multiple organ failure when patients lose tubular cell
function. In this setting, Naito et al. elegantly proved the
direct influence of LPS on tubular cell gene expression.
These authors demonstrated in vivo increased RNA‐
polymerase II density at TNF‐α, monocyte chemotactic
protein‐1 (MCP‐1) and heme oxygenase‐1 (HO‐1) loci
after LPS injection in mice. This effect was related to
selective histone methylation and was enhanced by dif-
ferent nephrotoxic stimuli [20]. These AKI‐associated
epigenetic alterations of tubular cells may be responsible
for the above‐mentioned increase in circulating inflam-
matory mediators.
Biomarkers of sepsis‐associated AKI
AKI is currently defined using the Risk, Injury, Failure,
Loss of kidney function, and End‐stage kidney disease
(RIFLE), Acute Kidney Injury Network (AKIN) and
Kidney Disease – Improving Global Outcomes (KDIGO)
criteria [21]: all these systems are based on the levels of
serum creatinine (SCr), estimated GFR (eGFR) and onurine output. However, these parameters are insensitive,
non‐specific and have a substantial latency, in particular
in patients with sepsis‐associated AKI. Indeed, sepsis per
se is known to decrease creatinine production; moreover,
the fluid overload that frequently characterizes septic
patients may be responsible for a further delay in SCr
increase. Urine output is also influenced by several
confounding factors: its rapid decrease not associated
with changes in GFR is currently classified as ‘transient’ or
‘subclinical’ AKI, with uncertain clinical significance
and not consistent with the presence of parenchymal
injury [22].
Several molecules have recently been proposed for the
early diagnosis of sepsis‐associated AKI. However, nu-
merous problems confound the validation of these mole-
cules in the clinical setting. First, these biomarkers are
always compared to the above‐mentioned defective clas-
sifications. Moreover, the current scarcity of effective
therapies limits the effect of early diagnosis on the
achievement of hard clinical endpoints. These two as-
pects concur to underestimate the diagnostic accuracy
of these new identified molecules. Finally, some of the
AKI biomarkers are (or are functionally associated with)
acute phase proteins and are influenced by the inflam-
matory state. On this basis, the cytokine storm observed
during sepsis may lead to a false‐positive interpretation.
However, despite these limits, several studies have dem-
onstrated substantial diagnostic improvements using dif-
ferent molecules.
Neutrophil gelatinase‐associated lipocalin (NGAL) is a
25 kDa protein belonging to the lipocalins, a class of sol-
uble factors involved in small molecule traffic. NGAL
binds to prokaryotic and eukaryotic siderophora, iron‐
chelating molecules involved in bacterial growth and tis-
sue differentiation, respectively. During the course of
AKI, NGAL is increased in both serum and urine. Serum
NGAL is mainly produced by hepatocytes and immune
cells, whereas urinary NGAL derives in part from serum
NGAL filtered by glomeruli and in part from NGAL re-
leased by kidney tubular epithelial cells following injury.
NGAL is the most extensively studied biomarker in sep-
tic AKI and is also frequently used as the control mol-
ecule when other proteins are investigated. NGAL has a
bimodal trend with a first peak before and a second peak
24–48 h after AKI onset [23]. A limitation of clinical
NGAL use is that its increase in both serum and urine
may be related to the presence of a systemic inflamma-
tory state including sepsis and not only to the develop-
ment of AKI. Indeed, it has been shown that patients
developing only sepsis or only AKI have similar serum
and urinary NGAL levels: by contrast, non‐AKI non‐
septic patients and those affected by both clinical
conditions are clearly classified [21]. To summarize
these studies, urinary and serum NGAL levels are
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of multiple organ failure) than with AKI incidence.
To reduce this limitation, some authors propose to
strengthen NGAL performance by combining it with
sepsis‐specific biomarkers. Lentini et al. measured cir-
culating levels of NGAL together with advanced oxi-
dation protein products (AOPP) in 98 consecutive
ICU patients. The authors found that NGAL values
were slightly higher in patients with only AKI than in
those with only sepsis without any significant differ-
ence: however, AOPP levels were able to distinguish be-
tween septic and non‐septic subjects and allowed a
correct classification for most patients. Similar results
were obtained coupling serum NGAL levels with endo-
toxin activity assay (EAA) results, which can identify LPS‐
induced neutrophilic responses in Gram‐negative bacteria,
septic shock [21]. Despite these encouraging data, a key
point for NGAL measurement still remains unresolved:
three different forms of NGAL have been isolated – a
25 kDa monomer, a 45 kDa dimer and a 135 kDa heterodi-
mer, conjugated with gelatinase. Currently, no commer-
cially available assays can discriminate between the
monomer, mainly released from tubular epithelial cells,
and the dimer, originating from neutrophils [22]. Future
development in this context may further increase the diag-
nostic accuracy of this molecule.
Triggering receptor expressed on myeloid cells
(TREM)‐1 is a membrane receptor belonging to the im-
munoglobulin superfamily and expressed on neutrophils
and monocytes. Its soluble form, sTREM, is massively
released in body fluids during sepsis, pneumonia, septic
arthritis, meningitis, peritonitis, and uterine cavity in-
fections. In septic patients, urinary sTREM is in-
creased 24–48 h before clinical evidence of AKI,
whereas a continuous increase in sTREM independ-
ently correlates with sepsis progression and with a
worse outcome [24]. However, similar to NGAL,
sTREM correlates with AKI as well as with systemic
inflammation and more studies are needed to detect
possible confounding factors.
The host SIRS is the cornerstone of sepsis develop-
ment: SIRS is caused by an immune system over‐reac-
tion to pathogens and induces a ‘cytokine storm’.
Additionally, recent findings have demonstrated that
several cytokines are involved in AKI development and
some are directly produced by renal cells. In a cohort
of ICU patients, Cho et al. found that IL‐8 and IL‐10
were increased in AKI patients independent of the
presence of sepsis. Interestingly, the authors found a
significant increase in soluble CD25 (IL‐2 receptor) in
septic AKI [15]. Soluble CD25 is a marker of T regula-
tory cell activity and it may correlate with the develop-
ment of a counter‐regulatory response leading to
immune paralysis.The combined use of urinary IGFBP‐7 and TIMP‐2
has recently been approved by the FDA as an early indi-
cator of AKI [18]. Other new biomarkers of AKI include
liver fatty acid binding protein (L‐FABP), IL‐18, netrin‐1,
kidney injury molecule‐1 (KIM‐1) and α1‐microglobulin.
Other circulating mediators, including CD40‐ligand,
Fas‐ligand, angiopoietin‐2 and presepsin (soluble CD14)
have been validated in septic patients as indicators of mor-
tality [21, 25]. In the next few years, the evolving field of
‘omics’ technologies (genomics, transcriptomics, proteo-
mics, and metabolomics) may lead to a system biology‐
based approach that could improve diagnostic strategies
for sepsis‐associated AKI.
Targeted therapeutic approaches for sepsis‐
associated AKI
Several clinical trials in patients with severe sepsis and
septic shock have failed to show an improvement in out-
comes. Despite the initial benefits of so‐called early goal‐
directed therapies, a prolonged series of therapeutic fail-
ures of promising strategies including corticosteroids,
activated protein C and the use of standard renal re-
placement therapies (RRT) has been observed. Septic pa-
tients still have an unacceptable high mortality and,
excluding antimicrobial agents, clinical management is
almost exclusively based on supportive therapies that are
not able to interfere with the underlying pathogenic
mechanisms of concomitant tissue damage and immu-
noparalysis. In this section, we summarize the more
recent advances in the therapeutic treatment of experi-
mental and clinical sepsis‐associated AKI.
Pharmacological agents
The severity of injury and the poor outcomes associated
with septic AKI worsen with delayed recognition of renal
dysfunction. Early identification of AKI in septic patients
is crucial because employed supportive and therapeutic
strategies are frequently nephrotoxic (e.g., antibiotics,
such as vancomycin and aminoglycosides, use of vaso-
pressor therapy without adequate fluid resuscitation,
etc.) and may additionally worsen the extent of the renal
injury. A recent clinical trial by Sood et al. [26] showed
that septic patients who had reversible or improved AKI
within 24 h of diagnosis had better survival rates than
patients who did not recover from AKI and even than
those who did not develop AKI at all. Most of the avail-
able interventions for AKI are based on prevention of
further renal insult or organ support (early administra-
tion of appropriate antimicrobial therapy, restoration of
tissue perfusion and optimization of the hemodynamic
status), but these standard treatment approaches have
not been effective in significantly reducing the incidence
of septic AKI. Furthermore, the emergence of antibiotic‐
resistant microbes as well as the increased clinical
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stand and to develop novel pharmacologic approaches to
successfully treat sepsis‐associated AKI.
The paradigm of sepsis‐associated organ dysfunction
and AKI has focused largely on specific cytokines and
their modulation or removal for improving outcome.
However, therapeutic approaches based on targeting
specific pathways known to contribute to the patho-
genesis of septic AKI have failed. Indeed, clinical tri-
als focused on antagonizing a single detrimental
mediator including anti‐endotoxin (LPS), TNF‐α, IL‐
1β, and TLR‐4 did not show any significant results
[27]. These failures may be, at least in part, explained
by the early‐deregulated host immune response medi-
ated by the activation of innate immunity followed by
a state of immunosuppression. For this reason, thera-
peutic approaches should consider the temporal pro-
file of the immune status in sepsis: the early blockade
of pro‐inflammatory pathways should be followed by
distinct therapies aimed at triggering the late activa-
tion of immunity. On this basis, Swaminathan et al.
recently reviewed emerging therapeutic approaches in
septic AKI, focusing on targeting early pro‐inflamma-
tory and late anti‐inflammatory processes [28]. The
suppression of early inflammation during sepsis‐asso-
ciated AKI could be obtained by using alkaline phos-
phatase. This enzyme is able to reduce inflammation
through dephosphorylation and thereby ‘detoxification’
of LPS, which is a key mediator of sepsis‐induced
organ failure, including AKI. Furthermore, alkaline
phosphatase catalyzes the conversion of adenosine tri-
phosphate into adenosine, a potent anti‐inflammatory
factor. The administration of recombinant alkaline
phosphatase reduced inflammation and the incidence
of septic AKI, but no changes in mortality rate were
observed [29]. In order to attenuate the early inflam-
matory response, some authors have also proposed
the use of cannabinoid 2 (CB2) receptor agonists
[30]. CB2 receptors are expressed on leukocytes and
regulate the immune system: their activation attenu-
ates leukocyte‐endothelial cell interaction and the
recruitment of leukocytes, thus reducing the amount
of circulating pro‐inflammatory mediators. Fibrates,
which are peroxisome proliferator‐activated receptor‐α
(PPARα) agonists, have been shown to ameliorate
sepsis induced by Gram‐negative bacteria by promot-
ing neutrophil recruitment [28]. Experimental studies
recently described the role of the cholinergic anti‐in-
flammatory pathway: stimulation of the vagus nerve
may attenuate cytokine release in sepsis, ischemia‐re-
perfusion injury and other states of inflammation
[31]. Moreover, nicotine (an α7 nicotinic acetylcholine
receptor agonist) has been shown to reduce mortality
in sepsis [28]. Other studies have demonstrated thatsoluble thrombomodulin was effective in preventing and
treating established AKI, an effect associated with reduced
leukostasis and endothelial cell permeability [32].
Later in the course of sepsis, the marked immunosup-
pressive state requires interventions that can stimulate the
immune response. IL‐7, which is critical for T‐cell devel-
opment and function, enhances immunity by increasing
the expression of cell adhesion molecules, facilitating
leukocyte trafficking to sites of infection [33]. Granulocyte
macrophage‐colony stimulating factor (GM‐CSF) restores
monocyte function and shortens the duration of mechan-
ical ventilation and length of ICU stay [34].
Extracorporeal blood purification techniques
In the last few decades, many studies have evaluated the
clinical and biological effects of different extracorporeal
blood purification techniques in sepsis‐associated AKI.
The use of RRT in septic patients has been evaluated
both for renal support and immunomodulation. Trad-
itional RRT indications are uremia, metabolic distur-
bances, fluid overload and electrolyte derangements.
However, several authors have proposed the use of
different RRT techniques to remove inflammatory medi-
ators potentially involved in AKI and distant organ dam-
age. Large clinical trials have suggested that, in septic
AKI, early initiation of RRT and the use of continuous
and not intermittent strategies are associated with a bet-
ter hemodynamic profile and outcome. However, the
timing of RRT initiation remains heterogeneous in clin-
ical practice and is not yet definitely supported by con-
sistent scientific evidence. Excessive delays in RRT
initiation have been associated with higher mortality
rates and with worsening of renal function. However, the
only published randomized controlled trial available
showed no significant differences in renal outcomes or
patient survival between early and late initiation of
dialysis [11]. The ongoing IDEAL‐ICU study (Initiation
of Dialysis EArly versus Late in the Intensive Care Unit)
will help define the optimal timing of RRT in septic AKI
patients [35]. The use of continuous renal replacement
therapies (CRRT) in septic AKI is still preferred because
of their relationship with better hemodynamic tolerabil-
ity and with enhanced renal recovery compared to inter-
mittent modalities. In a retrospective study examining
patients undergoing continuous therapies versus daily
hemofiltration, Sun et al. suggested that patients under-
going continuous veno‐venous hemofiltration (CVVH)
had a significant improvement in renal function, al-
though the all‐cause mortality rates were similar at
60 days [36].
Another relevant issue in RRT for sepsis‐associated
AKI is the dose of renal support, which has been evalu-
ated in different randomized clinical trials since the ini-
tial data from the Vicenza study in which a dose of
Dellepiane et al. Critical Care  (2016) 20:61 Page 8 of 1135ml/kg/h was associated with a better survival of AKI
patients, in particular in the presence of sepsis [37]. Un-
fortunately, subsequent studies, including the RENAL
and the Acute Renal Failure Trial Network (ATN) trials,
did not confirm these encouraging results [38, 39]. The
RENAL study [38] compared a dose of 25 vs. 40 ml/kg/h
in continuous veno‐venous hemodiafiltration (CVVHDF),
whereas the ATN study [39] compared 20 vs. 35ml/kg/h
in 3 times/week intermittent or continuous dialysis. Both
studies showed that an increased intensity of the RRT
dose had no beneficial effect on outcome (mortality was
the primary endpoint of both studies). However, in the
RENAL study, a post‐hoc analysis of septic patients
showed a tendency toward a reduction in mortality rate in
the group of patients treated with the higher‐intensity
approach (40ml/kg/h) [38]. Recently, the multicenter ran-
domized controlled trial, IVOIRE (hIgh VOlume in
Intensive caRE) evaluated the impact of high‐volume
hemofiltration (HVHF) on 28‐day mortality in critically ill
patients with septic shock and AKI. In this study, the
authors did not observe a reduction in 28‐day mortal-
ity or an early improvement in hemodynamic profile
or organ function using HVHF at 70 ml/kg/h com-
pared to standard‐volume hemofiltration at 35ml/kg/h
[40]. Even though the above‐mentioned studies led to
negative results in sepsis‐associated AKI, they have helped
define an optimal dose of dialysis, taking into consider-
ation the difference between prescribed and delivered
doses.
As stated before, the application of RRT in patients
with septic AKI also has the purpose of increasing the
clearance ofinflammatory mediators involved in tissue
injury. Over the years, different extracorporeal tech-
niques have been developed leadingto a wide range of
possible therapeutic approaches.
1. Standard RRT techniques (CVVH, CVVHD and
CVVHDF) using high molecular flow membranes
(HFM) or membranes with enhanced adsorption
capacity. HFM have an average cut‐off value of
approximately 30–40 kDa and are capable of
eliminating significant amounts of inflammatory
mediators including chemokines and cytokines in
the middle‐molecular weight category. Adsorptive
membranes, such as polymethyl methacrylate
(PMMA) and AN69ST, have also been used to
enhance endotoxin and cytokine clearance and
some clinical trials are underway in septic
patients with AKI [41]. However, we must
emphasize that these inflammatory mediators
have a very high generation rate: for this reason,
studies using CVVH failed to show any
significant modulation of plasma levels of
different cytokines [41].2. Convection‐based high‐volume techniques (HVHF)
are defined by a flow rate of more than 35 ml/kg/h.
Use of HVHF was the subject of a recent Cochrane
review [11]: selected trials comparing HVHF with a
standard dialysis dose did not show any improvement
in patient outcomes. Despite a reported increase in
hemodynamic stability and the absence of relevant
adverse effects, these studies did not support a
strong recommendation for the use of HVHF in
critically ill patients with severe sepsis and septic
shock. Furthermore, the application of HVHF may
potentially cause increased clearance of antibiotics
and other drugs, electrolyte disturbances and
depletion of micronutrients, which may all lead to a
less favorable outcome.
3. High cut‐off (HCO) membranes: these membranes
are porous enough to achieve the removal of larger
molecules (30–60 kDa) mainly by diffusion. Several
studies showed benefits of using HCO therapy,
such as improved immune cell function, removal
of inflammatory cytokines, and a reduction in
catecholamine dosage. An undesired effect is
albumin loss, which can be attenuated by albumin
replacement or by using HCO membranes in a
diffusive and not convective manner [42].
4. Hemoperfusion, hemoadsorption and plasma‐
adsorption: these techniques involve placement of a
sorbent, often a resin, in direct contact with blood
or plasma through an extracorporeal circuit. Most of
these devices are designed to combine the adsorption
strategy with standard RRT. The biocompatibility of
these devices is the main limitation for their use and
thrombocytopenia and bleeding risk are the most
relevant adverse effects [43].
Polymyxin B (PMX‐B) is a cationic polypeptide
antibiotic with activity against Gram‐negative
bacteria and high affinity for endotoxin, but its
intravenous use has been limited due to the well‐
known nephrotoxicity and neurotoxicity. PMX‐B
has been fixed and immobilized onto polystyrene
fiber in a hemoperfusion column cartridge that
allows endotoxin removal without toxic effects
[44]. The main mechanism of action is through
removal of circulating endotoxin, although its
effects are likely pleiotropic including the entrapment
of inflammatory cells, such as monocytes and
neutrophils, and the clearance of cytokines TNF‐α
and IL‐6 with a consequent reduction in the
intracellular mechanisms of apoptosis. Cruz et al.
[44] published a meta‐analysis showing that PMX‐B
hemoperfusion used in patients with severe sepsis led
to an improvement in hemodynamics as measured by
mean arterial pressure as well as in oxygenation.
These results were observed in the Early Use of
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shock (EUPHAS) trial in Europe that confirmed
preliminary data coming from the Japanese
experience [45]. However, the sample size of these
studies was small and confirmation of these
clinical benefits in larger studies is still awaited.
The first randomized, controlled, diagnostic‐
directed and theragnostic trial, named EUPHRATES
(Evaluating the Use of Polymyxin B Hemoperfusion in
a Randomized controlled trial of Adults Treated for
Endotoxemia and Septic shock) is still ongoing in the
US and Canada [46].
The LPS adsorber is a medical device designed for
extracorporeal use, which contains a series of porous
polyethylene plates coated with a peptide specific to
endotoxin. Yaroustovsky et al. compared the LPS
adsorber and PMX‐B hemoperfusion in patients
with Gram‐negative sepsis and reported no significant
differences in outcome (small number of enrolled
patients) [47].
CytoSorb is a highly adsorptive and biocompatible
polymer able to remove multiple inflammatory
mediators from the bloodstream. Animal studies
have elegantly shown that therapeutic apheresis
using CytoSorb can restore chemokine gradients
toward infected tissue and away from healthy organs
through a sort of leukocyte trafficking control [48].
Coupled plasma filtration adsorption (CPFA) is an
extracorporeal treatment based on non‐specific
adsorption of cytokines and other pro‐inflammatory
mediators onto a specially designed resin cartridge
that is in direct contact with filtered plasma. This
system is coupled in series with a standard RRT
circuit. Some studies have shown interesting results
concerning an improvement in hemodynamics,
microvascular derangement and respiratory
parameters during the course of CPFA [49].5. The existing extracorporeal techniques are mainly
based on plasma filtration and consequently on
substitution of the glomerular function of the
kidney. However, standard RRT techniques did not
allow some specific functions of transport, metabolic
and endocrine activities of tubular epithelial cells to
be replaced. To overcome this limitation, Tumlin
and coworkers developed a renal assist device (RAD)
using a polysulfone filter containing living kidney
tubular epithelial cells coupled with a conventional
RRT circuit. These authors validated this bio‐
engineered device in several in vivo models
demonstrating that septic animals affected by AKI
and treated with the RAD maintained reabsorption of
K+, HCO3−, and glucose, as well as the excretion of
ammonia and normal levels of 1,25‐OH‐vitamin
D3 [50]. Moreover, the RAD modulates systemicinflammation by regulating circulating levels of
several cytokines. Based on these preclinical studies, a
randomized controlled trial was performed and
showed that the RAD induced about a 50 % reduction
in 180‐day mortality when compared to standard
CVVH [50]. Moreover, the RAD was able to
modulate plasma levels of several cytokines,
including G‐CSF, IL‐6, and IL‐10, thus improving
both the early SIRS and late immunoparalysis
typical of septic AKI. Of interest, the clinical trial
with the RAD was prematurely interrupted because
the investigators also observed a significant decrease
in mortality using a sham cartridge not containing
viable tubular cells. Following this observation, the
same authors developed the so‐called selective
cytophoretic device (SCD) able to sequestrate
activated leukocytes within the membrane,
inhibiting the release of harmful mediators.
Preliminary studies indicated that, when coupled
to a standard hemofilter, SCD reduced mortality
and dialysis dependence in septic patients.
However, the beneficial effects of SCD were
observed only when citrate but not heparin was
used as the anticoagulant strategy [51]. This
finding emphasizes the potential anti‐inflammatory
properties of citrate, which may at least in part
explain the data on a reduction in mortality in
clinical trials in ICU patients subjected to RRT
with citrate [51].
Stem cell therapies
Stem cell‐based therapies have been proposed in almost
all fields of medicine with controversial success. One of
the major limitations of this approach comes from the
host immune reaction as well as from the possibility of
cell dysplasia and tumorigenesis or other maladaptive re-
sponses including maldifferentiation, tissue fibrosis, cal-
cification and innate immunity dysregulation. For these
reasons, despite a large number of experimental studies,
effective clinical results are still lacking, even in the field
of sepsis [52].
Bone marrow‐derived stem cells of both mesenchymal
and hematopoietic origin have been extensively studied
in different experimental models of AKI. Mesenchymal
stem cells are a heterogeneous population that can be
isolated from a variety of adult tissues of mesodermal
origin, including bone marrow, adipose tissue, pla-
centa, umbilical cord, dental pulp and synovia. For
their regenerating and immune‐modulatory effects,
mesenchymal stem cells have been tested in several
experimental models of acute tissue injury models in-
cluding AKI and kidney transplantation [52]. Mesen-
chymal stem cells are able to sense inflammation
through the expression of cytokine receptors and
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duce M2 macrophages as well as T‐regulatory cells
[52]. Mesenchymal stem cell‐related anti‐inflammatory
M2 macrophages have also been induced in sepsis
models. Moreover, mesenchymal stem cells improved
monocyte and neutrophil phagocytosis and reduced
bacterial load in different organs (peritoneal cavity,
blood, spleen and liver) [53].
Endothelial progenitor cells are circulating committed
cells involved in vascular regeneration processes. The
therapeutic use of endothelial progenitor cells may be of
particular interest in sepsis because of their major role
in protection from endothelial dysfunction. Moreover,
sepsis is associated with a severe depletion in the
endothelial progenitor cell circulating pool and this
impairment independently correlates with a worse
outcome [54].
Recent studies have suggested that most of the benefi-
cial effects of mesenchymal stem cell and endothelial
progenitor cell infusions are observed in the absence of
cell engraftment within injured tissues [55]. In addition,
the infusion of stem cell supernatants induced a protect-
ive effect similar to that observed after whole cell trans-
plantation [55]. Taken together, these results suggest
that endocrine/paracrine factors promote the regenera-
tive effects of stem cells. In this setting, recent studies
have demonstrated the potential role of microvesicles re-
leased from stem cells in tissue regeneration following
AKI. Microvesicles are cell fragments involved in cell‐to‐
cell communication that are able to shuttle different
RNA subsets (mRNA and microRNA), proteins and
lipids. In different experimental AKI models, microvesi-
cle administration was associated with improved renal
function, histological lesions and survival, preventing the
progression toward end‐stage CKD [56]. These regenera-
tive effects were partially due to the epigenetic repro-
gramming of target injured renal cells through the
horizontal transfer of mRNA and microRNA [57].
Conclusion
Experimental and clinical studies have proven the pres-
ence of a detrimental cross‐talk between sepsis, the
systemic inflammatory response to infection, and the de-
velopment of AKI. Sepsis represents the main cause of
renal dysfunction in critically ill patients admitted to the
ICU. From a pathogenic point of view, it has been
shown that the damage of renal endothelial and tubular
epithelial cells during sepsis occurs in the absence of evi-
dent signs of tissue hypoperfusion. Indeed, septic AKI
develops in the presence of a normal or even increased
RBF. These results suggest that the pathogenic mech-
anisms of septic AKI are associated with the detri-
mental activity of circulating pro‐inflammatory and
pro‐apoptotic mediators that directly bind to renalresident cells. In particular, the onset of apoptosis,
necrosis, necroptosis, autophagy, mitophagy and cell
cycle arrest has been identified as the main mechanism of
tubular injury during sepsis. Early identification of
sepsis‐associated AKI using new biomarkers (‘omics’
technologies) may improve patient outcomes. More-
over, new therapeutic strategies based on pharmacological
agents, extracorporeal blood purification techniques and
stem cell infusion have been developed and exciting clin-
ical results are expected in the next few years.
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